After all the tumors in the control group reached the ethical endpoint, we re-challenged the tumor-free mice from the Xcl1-E6E7 and E6E7 treatment group with a second subcutaneous implantation of TC-1 cells to evaluate the long-term preventive efficacy of the vaccine. The gene discussed is XCL1; the disease is neoplasm.